Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC-841 in Advanced Solid Tumors
NCT06352359Phase 1Recruiting
- Sponsor
- OncoC4
- Start
- Aug 2024
- Primary completion
- Sep 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ONC-841 in solid tumor (advanced stage), sponsored by OncoC4. Primary endpoints: Dose Limiting Toxicity at 28 days and Maximum Toxicity Dose at 28 days. Started Aug 2024; status: recruiting.
02
Drugs
ONC-841
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06352359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06352359.